Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors

Journal of Patient-Reported Outcomes

Table 2 Treatment and medical history

Characteristic	Patients (N = 202)
Time since NET diagnosis,^a mean (SD) years	6.9 (5.0)
Diagnosed with CS or experienced CS-related symptoms, n (%)	181 (89.6)
Type of LA SSA injection currently receiving, n (%)
Somatuline depot (lanreotide)	82 (40.6)
Sandostatin LAR (octreotide)	120 (59.4)
Length of time receiving current injection, n (%)
Less than a year	44 (21.8)
1 to < 5 years	98 (48.5)
5 to < 8 years	32 (15.8)
8 years or more	28 (13.9)
Experience receiving lanreotide and octreotide, n (%)^b	41 (20.3)
Location of most recent injection, n (%)
Community (nonacademic) clinic/office/treatment center	101 (50.0)
Academic or university-associated clinic/office/treatment center	85 (42.1)
At home by a visiting nurse	5 (2.5)
Other	10 (5.0)
Don’t know/not sure	1 (0.5)
Primary location of NET, n (%)
Gastrointestinal^c	137 (67.8)
Unknown primary site^d	21 (10.4)
Lung	17 (8.4)
Pancreas	12 (5.9)
Liver^e	3 (1.5)
Kidney	2 (1.0)
Ovary	1 (0.5)
Other	7 (3.5)
Don’t know/don’t remember	2 (1.0)

CS Carcinoid syndrome, LA SSA long-acting somatostatin analog, LAR long-acting release, NET neuroendocrine tumors; SD standard deviation
^aN = 200
^bRespondents were asked whether they had ever received octreotide and ever received lanreotide; 41 respondents had received both types of LA SSA
^cIncludes appendix (n = 8), large intestine (colon, large bowel) (n = 13), small intestine (small bowel, duodenum, jejunum, ileum) (n = 109), stomach (n = 5), and rectum (n = 2)
^dThe primary tumor site was unknown to the physician at diagnosis
^ePrimary NETs of the liver are extremely rare, and respondents with metastatic disease to the liver may have reported their tumors as being primary to the liver. Metastatic disease to the liver cannot be ruled out for these responses